Progress in liver transplantation for intrahepatic cholangiocarcinoma
10.3969/j.issn.1674-7445.2023144
- VernacularTitle:肝移植治疗肝内胆管癌的研究进展
- Author:
Guoying WANG
1
;
Caihua HE
1
Author Information
1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
- Publication Type:Editorial
- Keywords:
Intrahepatic cholangiocarcinoma;
Liver transplantation;
Hepatocellular carcinoma;
Hepatectomy;
Neoadjuvant therapy;
Recurrence;
Chemotherapy;
Immunotherapy;
Immune checkpoint inhibitor
- From:
Organ Transplantation
2023;14(6):789-796
- CountryChina
- Language:Chinese
-
Abstract:
Intrahepatic cholangiocarcinoma (ICC) is a primary malignant tumor of the liver, secondary to hepatocellular carcinoma, and its incidence tends to elevate worldwide. Hepatectomy is the optimal surgical regimen for ICC patients. ICC is considered as a contraindication for liver transplantation due to high tumor recurrence rate and poor survival outcome. At present, multiple significant progresses have been made in liver transplantation for ICC. For strictly-selected ICC patients, liver transplantation or liver transplantation after neoadjuvant therapy has achieved encouraging survival outcomes. Meantime, with the improvement of prognostic risk stratification of liver transplantation for ICC, the inclusion criteria of ICC candidates undergoing liver transplantation will be further optimized. In addition, the advancement of modern multi-mode comprehensive treatment of ICC will further guide the selection of neoadjuvant therapy before liver transplantation for ICC. The application of immune checkpoint inhibitors in ICC before liver transplantation is also an important research direction in the future. In this article, clinical prognosis of liver transplantation for ICC, prognostic risk factors and inclusion criteria of ICC candidates undergoing liver transplantation, and the ongoing trials and existing challenges were summarized, aiming to provide reference for liver transplantation for ICC and improve the quality of life for ICC patients.
